Cardinal Health Inc (CAH) KPIs and segments
Close on Nov 18, 2026Market cap $64.73BP/E 38.5Yield 0.73%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Cardinal Health · năm tài chính kết thúc ngày 30 tháng 6
Nhìn nhanh KPI của Cardinal Health: 33 chỉ số vận hành, trong đó có Other Growth Businesses Revenue, Pharmaceutical & Specialty Solutions Reported Revenue và Global Medical Products & Distribution Segment Profit, lấy từ 216 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Cardinal Health kết thúc ngày 30 tháng 6 — Q1 FY27 = CQ3 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical and Specialty Solutions($M) | 58,848 | 56,111 | 60,669 | 59,205 | 55,372 | 50,433 | 50,849 | 47,990 | 55,607 | 50,622 | 53,202 | ||
GMPD($M) | 3,128 | 3,148 | 3,259 | 3,184 | 3,199 | 3,160 | 3,154 | 3,123 | 3,109 | 3,113 | 3,127 | ||
Other Operating Segment($M) | 1,721 | 1,706 | 1,724 | 1,641 | 1,609 | 1,304 | 1,283 | 1,186 | 1,172 | 1,154 | 1,135 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)2 | |||||||||||||
United States($M) | 63,269 | 60,542 | 65,217 | 63,611 | 59,746 | 54,498 | 54,858 | 51,891 | 59,448 | 54,464 | 57,049 | ||
Non-US($M) | 428 | 423 | 435 | 419 | 434 | 399 | 428 | 408 | 440 | 425 | 415 | ||
Pharmaceutical and Specialty Solutions($M) | 645 | 784 | 687 | 667 | 535 | 662 | 531 | 530 | 482 | 582 | 495 | ||
Other Operating Segment($M) | 183 | 179 | 179 | 166 | 160 | 134 | 118 | 104 | 111 | 110 | 106 | ||
GMPD($M) | 150 | 25 | 37 | 46 | 70 | 39 | 18 | 8 | 47 | 22 | 11 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)2 | |||||||||||||
Pharmaceutical and Specialty Solutions($M) | 1,402 | 1,516 | 1,426 | 1,348 | 1,199 | 1,266 | 1,099 | 1,081 | |||||
GMPD($M) | 703 | 543 | 539 | 551 | 591 | 526 | 530 | 519 | |||||
Other Operating Segment($M) | 457 | 438 | 433 | 420 | 414 | 329 | 314 | 302 | |||||
Other Operating Segment($M) | -48 | -25 | -23 | -15 | -36 | -18 | -22 | -12 | |||||
GMPD($M) | -60 | -32 | -23 | -19 | -61 | -28 | -21 | -23 | |||||
Pharmaceutical and Specialty Solutions($M) | -68 | -37 | -23 | -32 | -62 | -33 | -12 | -11 | |||||
Pharmaceutical and Specialty Solutions($M) | 40,777 | 41,032 | 43,405 | 38,683 | 37,313 | 35,734 | 32,125 | 29,215 | 29,149 | 30,496 | |||
GMPD($M) | 6,651 | 6,888 | 6,993 | 7,133 | 6,889 | 7,201 | 7,055 | 7,148 | 7,047 | 7,357 | |||
Other Operating Segment($M) | 4,098 | 4,065 | 4,073 | 4,049 | 4,045 | 2,726 | 2,720 | 2,611 | 2,606 | 2,692 | |||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)2 | |||||||||||||
Other Growth Businesses Revenue ($M)($M)5 | 1,764 | 1,721 | 1,706 | 1,724 | 1,641 | 1,609 | 1,304 | 1,283 | 1,186 | 1,172 | 1,154 | 1,135 | |
at-Home Solutions Revenue ($M)($M) | 1,146 | 1,108 | 1,128 | 1,185 | 1,115 | 1,089 | 817 | 835 | 739 | 733 | 730 | 739 | |
Nuclear and Precision Health Solutions (NPHS) Revenue ($M)($M) | 505 | 497 | 478 | 440 | 436 | 430 | 403 | 372 | 373 | 363 | 352 | 330 | |
OptiFreight Logistics Revenue ($M)($M) | 113 | 116 | 100 | 99 | 90 | 90 | 84 | 76 | 74 | 76 | 72 | 66 | |
Other Growth Businesses Reported Revenue Growth YoY (%)(%) | 7.0% | 7.0% | 31.0% | 34.0% | 38.0% | 37.0% | 13.0% | 13.0% | 13.0% | 15.0% | 14.0% | 11.0% | |
Other Growth Businesses Segment Profit ($M)($M)3 | 193 | 183 | 179 | 179 | 166 | 160 | 134 | 118 | 104 | 111 | 110 | 106 | |
Other Growth Businesses Segment Profit Margin (%)(%) | 10.9% | 10.6% | 10.5% | 10.4% | 10.1% | 9.9% | 10.3% | 9.2% | 8.8% | 9.5% | 9.5% | 9.3% | |
Other Growth Businesses Margin Change YoY (bps)(bps) | 82 | 82 | 21 | 118 | 135 | 21 | 75 | -14 | -36 | ||||
Other Growth Businesses Reported Profit Growth YoY (%)(%) | 16.0% | 14.0% | 34.0% | 52.0% | 60.0% | 44.0% | 22.0% | 11.0% | 8.0% | 11.0% | 9.0% | 10.0% | |
Pharmaceutical & Specialty Solutions Reported Revenue Growth YoY (%)(%)5 | 6.0% | 6.0% | 11.0% | 19.0% | 23.0% | 0.0% | 0.0% | -4.0% | -5.0% | 13.0% | 9.0% | 12.0% | |
GLP-1 Medications Revenue Growth Contribution (Percentage Points)(%) | 5.0% | 5.0% | 6.0% | ||||||||||
IRA WAC Price Reductions Revenue Growth Impact (Percentage Points)(%) | -4.0% | -5.0% | -6.0% | ||||||||||
Pharmaceutical & Specialty Solutions Reported Profit Growth YoY (%)(%) | 17.0% | 21.0% | 18.0% | 29.0% | 26.0% | 11.0% | 14.0% | 7.0% | 16.0% | 8.0% | 0.0% | 10.0% | |
Pharmaceutical & Specialty Solutions Margin Change YoY (bps)(bps) | 12 | 9 | 9 | 9 | 3 | 14 | 16 | 11 | 20 | ||||
The Specialty Alliance Physician MSO Common Unit Repurchases ($M)($M) | 4 | 18 | 5 | 6 | 16 | 19 | 0 | 0 | |||||
Global Medical Products & Distribution (GMPD) Segment Profit Margin (%)(%)2 | 1.0% | 4.8% | 0.8% | 1.1% | 1.4% | 2.2% | 1.2% | 0.6% | 0.3% | 1.5% | 0.7% | 0.4% | |
GMPD Segment Profit Margin Change YoY (bps)(bps) | -41 | 96 | -44 | 57 | 118 | 33 | 52 | 22 | -14 | ||||
GMPD Reported Segment Profit Growth YoY (%)(%) | -28.0% | 91.0% | -36.0% | 106.0% | 47.0% | 77.0% | |||||||
Pharmaceutical and Specialty Solutions — Segment Revenue ($M)($M)7 | 62,582 | 58,848 | 56,111 | 60,669 | 59,205 | 55,372 | 50,433 | 50,849 | 47,990 | 55,607 | 50,622 | 53,202 | |
Pharmaceutical & Specialty — Cost of Products Sold ($M)($M) | 61,001 | 57,446 | 54,595 | 59,243 | 57,857 | 54,173 | 49,167 | 49,750 | 46,909 | ||||
Pharmaceutical & Specialty — Segment SG&A Expenses ($M)($M) | 798 | 757 | 732 | 739 | 681 | 664 | 604 | 568 | 551 | ||||
Pharmaceutical & Specialty — Total Segment Expenses ($M)($M) | 61,799 | 58,203 | 55,327 | 59,982 | 58,538 | 54,837 | 49,771 | 50,318 | 47,460 | ||||
Pharmaceutical & Specialty — Segment Profit Margin (%)(%) | 1.3% | 1.1% | 1.4% | 1.1% | 1.1% | 1.0% | 1.3% | 1.0% | 1.1% | 0.9% | 1.2% | 0.9% | |
Pharmaceutical & Specialty — Segment Goodwill ($M)($M) | 9,729 | 9,695 | 9,668 | 9,861 | 7,966 | 7,943 | 7,736 | 4,318 | 3,555 | 3,555 | 3,618 | ||
Pharmaceutical & Specialty — Segment D&A ($M)($M) | 60 | 62 | 70 | 64 | 61 | 68 | 44 | 46 | 27 | ||||
Pharmaceutical & Specialty — Segment Additions to PP&E ($M)($M) | 45 | 68 | 37 | 23 | 32 | 62 | 33 | 12 | 11 | ||||
Global Medical Products and Distribution (GMPD) — Segment Revenue ($M)($M)6 | 3,190 | 3,128 | 3,148 | 3,259 | 3,184 | 3,199 | 3,160 | 3,154 | 3,123 | 3,109 | 3,113 | 3,127 | |
GMPD — Cost of Products Sold ($M)($M) | 2,636 | 2,425 | 2,605 | 2,720 | 2,633 | 2,608 | 2,634 | 2,624 | 2,604 | ||||
GMPD — Segment SG&A Expenses ($M)($M) | 521 | 553 | 518 | 502 | 505 | 521 | 487 | 512 | 511 | ||||
GMPD — Total Segment Expenses ($M)($M) | 3,157 | 2,978 | 3,123 | 3,222 | 3,138 | 3,129 | 3,121 | 3,136 | 3,115 | ||||
GMPD — Segment Goodwill ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
GMPD — Segment D&A ($M)($M) | 56 | 55 | 54 | 55 | 55 | 47 | 56 | 60 | 49 | ||||
GMPD — Segment Additions to PP&E ($M)($M) | 16 | 60 | 32 | 23 | 19 | 61 | 28 | 21 | 23 | ||||
Other Segment (NPHS, at-Home & OptiFreight) — Total Segment Expenses ($M)($M)5 | 1,571 | 1,538 | 1,527 | 1,545 | 1,475 | 1,449 | 1,170 | 1,165 | 1,082 | ||||
Other Segment — Cost of Products Sold ($M)($M) | 1,303 | 1,264 | 1,268 | 1,291 | 1,221 | 1,195 | 975 | 969 | 884 | ||||
Other Segment — Segment SG&A Expenses ($M)($M) | 268 | 274 | 259 | 254 | 254 | 254 | 195 | 196 | 198 | ||||
Other Segment — Segment Goodwill ($M)($M) | 1,814 | 1,747 | 1,747 | 1,748 | 1,745 | 1,748 | 1,170 | 1,170 | 1,170 | 1,170 | 1,170 | ||
Other Segment — Segment D&A ($M)($M) | 28 | 27 | 26 | 30 | 29 | -1 | 31 | 40 | 18 | ||||
Other Segment — Segment Additions to PP&E ($M)($M) | 20 | 48 | 25 | 23 | 15 | 36 | 18 | 22 | 12 | ||||
Total Reportable Segments Profit ($M)($M)7 | 1,009 | 978 | 988 | 903 | 879 | 765 | 835 | 667 | 642 | 640 | 714 | 612 | |
Total Segment Cost of Products Sold ($M)($M) | 64,940 | 61,135 | 58,468 | 63,254 | 61,711 | 57,976 | 52,776 | 53,343 | 50,397 | ||||
Total Segment SG&A Expenses ($M)($M) | 1,587 | 1,584 | 1,509 | 1,495 | 1,440 | 1,439 | 1,286 | 1,276 | 1,260 | ||||
Total Segment Expenses ($M)($M) | 66,527 | 62,719 | 59,977 | 64,749 | 63,151 | 59,415 | 54,062 | 54,619 | 51,657 | ||||
Corporate Inter-Segment Revenue Elimination ($M)($M) | -23 | -25 | -25 | -25 | -21 | -21 | -19 | -22 | -22 | -21 | -21 | -22 | |
Corporate Unallocated Assets ($M)($M) | 5,984 | 5,773 | 4,704 | 3,612 | 5,363 | 4,875 | 4,210 | 5,102 | 4,085 | 6,319 | 5,335 | 5,738 | |
Corporate Unallocated D&A ($M)($M) | 103 | 97 | 98 | 85 | 88 | 95 | 76 | 46 | 88 | ||||
Corporate Additions to PP&E ($M)($M) | 76 | 88 | 53 | 62 | 42 | 73 | 47 | 44 | 44 | ||||
United States Revenue ($M)($M)2 | 67,113 | 63,269 | 60,542 | 65,217 | 63,611 | 59,746 | 54,498 | 54,858 | 51,891 | 59,448 | 54,464 | 57,049 | |
United States Property and Equipment, Net ($M)($M) | 2,579 | 2,607 | 2,494 | 2,445 | 2,396 | 2,422 | 2,106 | ||||||
International Property and Equipment, Net ($M)($M) | 420 | 424 | 434 | 432 | 435 | 436 | 423 | ||||||
Legacy Pharmaceutical Segment Revenue (Pre-Q3 FY24 Structure, $M)($M)1 | 53,520 | ||||||||||||
Legacy Medical Segment Revenue (Pre-Q3 FY24 Structure, $M)($M)1 | 3,928 | ||||||||||||
Non-GAAP Operating Earnings ($M)($M)13 | 1,001 | 935 | 956 | 877 | 857 | 719 | 807 | 635 | 625 | 605 | 667 | 585 | |
Non-GAAP Operating Earnings Growth YoY (%)(%) | 17.0% | 30.0% | 18.0% | 38.0% | 37.0% | 19.0% | 21.0% | 9.0% | 12.0% | 14.0% | 5.0% | 17.0% | |
Non-GAAP Gross Margin ($M)($M) | 2,596 | 2,560 | 2,498 | 2,398 | 2,318 | 2,203 | 2,122 | 1,941 | 1,902 | 1,882 | 1,935 | 1,854 | |
Non-GAAP SG&A Expenses ($M)($M) | 1,595 | 1,625 | 1,542 | 1,520 | 1,461 | 1,484 | 1,315 | 1,306 | 1,277 | 1,277 | 1,269 | 1,269 | |
Non-GAAP Pre-Tax Earnings ($M)($M) | 934 | 882 | 840 | 799 | 788 | 676 | 741 | 597 | 598 | 595 | 640 | 592 | |
Non-GAAP Net Earnings Attributable to Cardinal Health ($M)($M) | 759 | 682 | 750 | 624 | 611 | 501 | 568 | 468 | 460 | 450 | 511 | 464 | |
Non-GAAP Effective Tax Rate (%)(%) | 18.5% | 22.5% | 10.2% | 21.4% | 21.9% | 26.3% | 22.4% | 21.4% | 23.0% | 24.6% | 19.9% | 21.4% | |
Non-GAAP Diluted EPS ($)($) | 3.26 | 2.91 | 3.17 | 2.63 | 2.55 | 2.08 | 2.35 | 1.93 | 1.88 | 1.84 | 2.09 | 1.89 | |
Non-GAAP Diluted EPS Growth YoY (%)(%) | 28.0% | 40.0% | 35.0% | 36.0% | 36.0% | 13.0% | 13.0% | 2.0% | 9.0% | 29.0% | 14.0% | 31.0% | |
Pre-Tax Adjustment: Amortization & Other Acquisition-Related Costs ($M)($M)1 | 182 | 121 | 114 | 130 | 104 | 133 | 152 | 105 | 74 | 77 | 80 | 63 | |
Pre-Tax Adjustment: Acquisition-Related Cash & Share-Based Compensation ($M)($M)1 | 94 | 44 | 112 | 67 | 64 | 106 | 20 | ||||||
Pre-Tax Adjustment: Restructuring & Employee Severance ($M)($M)1 | 23 | 40 | 25 | 21 | 20 | 27 | 28 | 9 | 24 | 69 | 53 | 28 | |
Pre-Tax Adjustment: Impairments & (Gain)/Loss on Disposal of Assets ($M)($M)1 | -4 | 4 | 185 | -14 | 2 | 33 | -17 | 3 | -1 | 8 | 84 | 1 | |
Pre-Tax Adjustment: Litigation (Recoveries)/Charges, Net ($M)($M)1 | -47 | -3 | 11 | -18 | 0 | -9 | -105 | -31 | -40 | 50 | 80 | -11 | |
Non-GAAP Adjusted Free Cash Flow ($M)($M)1 | 1,583 | 1,446 | 1,697 | 543 | 1,285 | 1,304 | 2,799 | -250 | -1,361 | 1,819 | 107 | 1,038 | |
Cash Payments Related to Litigation Matters, Net ($M)($M) | 338 | 0 | 15 | -18 | 404 | -3 | 1 | 245 | 376 | -70 | 246 | -27 | |
Full-Year Non-GAAP Diluted EPS Guidance — Low ($)($)22 | 12.80 | 12.40 | 10.70 | 10.15 | 9.65 | 9.30 | 8.05 | 7.85 | 7.75 | ||||
Full-Year Non-GAAP Diluted EPS Guidance — High ($)($) | 13 | 12.60 | 10.80 | 10.35 | 9.85 | 9.50 | 8.15 | 8 | 7.90 | ||||
Full-Year Non-GAAP Adjusted FCF Guidance — Low ($B)(M) | 3.50 | 3.50 | 3.30 | 3 | 3 | 2.75 | 1.50 | 1 | 1 | ||||
Full-Year Non-GAAP Adjusted FCF Guidance — High ($B)(M) | 4 | 4 | 3.70 | 3.50 | 3.50 | 3.25 | 1.50 | 1.50 | 1.50 | ||||
Pharma & Specialty Profit Growth Guidance — Low (%)(%) | 10.0% | 8.0% | 22.0% | 20.0% | 16.0% | 11.0% | 11.5% | 10.0% | 4.0% | ||||
Pharma & Specialty Profit Growth Guidance — High (%)(%) | 12.0% | 11.0% | 23.0% | 22.0% | 19.0% | 13.0% | 12.5% | 12.0% | 6.0% | ||||
GMPD Revenue Growth Guidance — Low (%)(%) | 2.0% | 2.0% | 1.0% | 1.0% | 2.0% | 2.0% | 2.0% | 2.0% | 2.0% | ||||
GMPD Revenue Growth Guidance — High (%)(%) | 4.0% | 4.0% | 3.0% | 3.0% | 4.0% | 4.0% | 4.0% | 4.0% | 4.0% | ||||
GMPD Segment Profit Guidance — Low ($M)($M) | 200 | 200 | 150 | 150 | |||||||||
GMPD Segment Profit Guidance — High ($M)($M) | 220 | 220 | 150 | 150 | |||||||||
Other (Growth Businesses) Revenue Growth Guidance — Low (%)(%) | 12.0% | 11.0% | 26.0% | 26.0% | 26.0% | 26.0% | 17.0% | 10.0% | 10.0% | ||||
Other (Growth Businesses) Revenue Growth Guidance — High (%)(%) | 14.0% | 13.0% | 28.0% | 28.0% | 28.0% | 28.0% | 19.0% | 12.0% | 12.0% | ||||
Other (Growth Businesses) Profit Growth Guidance — Low (%)(%) | 17.0% | 15.0% | 36.0% | 33.0% | 29.0% | 25.0% | 16.0% | 10.0% | 10.0% | ||||
Other (Growth Businesses) Profit Growth Guidance — High (%)(%) | 20.0% | 18.0% | 38.0% | 35.0% | 31.0% | 27.0% | 18.0% | 10.0% | 10.0% | ||||
Full-Year Capital Expenditures Guidance — Low ($M)($M) | 700 | 700 | 600 | 600 | 600 | 600 | 500 | 500 | 500 | ||||
Full-Year Capital Expenditures Guidance — High ($M)($M) | 700 | 700 | 650 | 650 | 650 | 600 | 550 | 550 | 550 | ||||
Full-Year Share Repurchases Guidance ($M)($M) | 1,000 | 1,000 | 1,000 | 750 | 750 | 750 | 750 | 750 | 750 | ||||
Full-Year Net Interest & Other Guidance — Low ($M)($M) | 240 | 240 | 340 | 325 | 325 | 275 | 200 | 200 | 140 | ||||
Full-Year Net Interest & Other Guidance — High ($M)($M) | 290 | 290 | 340 | 325 | 325 | 275 | 215 | 230 | 170 | ||||
Full-Year Non-GAAP Effective Tax Rate Guidance — Low (%)(%) | 18.5% | 19.0% | 19.0% | 21.0% | 22.0% | 22.0% | 23.0% | 23.0% | 23.0% | ||||
Full-Year Non-GAAP Effective Tax Rate Guidance — High (%)(%) | 19.5% | 20.0% | 19.0% | 23.0% | 24.0% | 24.0% | 23.5% | 24.0% | 24.0% | ||||
Full-Year Diluted Shares Guidance — Low (M)(M) | 231 | 233 | 237 | 237 | 238 | 238 | 242 | 243 | 243 | ||||
Full-Year Diluted Shares Guidance — High (M)(M) | 232 | 233 | 237 | 238 | 238 | 240 | 242 | 243 | 243 | ||||
Total Accrued Opioid Litigation Settlement Liability ($M)($M)2 | 3,900 | 4,300 | 4,300 | 4,300 | 4,300 | 4,900 | 4,900 | 4,900 | 5,000 | 5,400 | 5,300 | 5,470 | |
Current Portion of Opioid Settlement Liability ($M)($M) | 197 | 468 | 477 | 477 | 486 | 628 | 636 | 636 | 789 | 643 | 438 | 420 | |
Accrued Restructuring Reserve Balance ($M)($M) | 45 | 55 | 73 | 76 | 71 | 79 | 82 | 75 | 94 | 97 | 70 | 39 | |
Remaining Share Repurchase Authorization ($M)($M)3 | 5,893 | 1,393 | 1,793 | 1,993 | 2,443 | 2,743 | 2,743 | 3,118 | 3,193 | 3,493 | 3,493 | ||
Total Common Shares Repurchased (Shares) | 2,158,685 | 1,960,633 | 928,476 | 2,318,707 | 2,025,433 | 20 | 2,979,261 | 670,481 | 2,737,035 | 419 | 314 | ||
Common Shares Repurchased Under Publicly Announced Programs (Shares) | 2,158,582 | 1,960,591 | 928,419 | 2,318,688 | 2,025,385 | 2,979,191 | 670,119 | 2,735,978 | |||||
Weighted-Average Price Paid per Share Repurchased ($)($) | 232 | 185 | 215 | 184 | 148 | 147 | 126 | 112 | 110 | 102 | 107 | ||
Federal Prime Contract Obligations to Cardinal Health ($M)($M)4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Department of Defense (DoD / Defense Logistics Agency) Obligations ($M)($M) | 34.6 | 121 | 105 | 84.6 | 131 | 92.6 | 93.3 | 93.5 | 144 | 105 | 115 | 94.4 | |
Department of Veterans Affairs (VA) Obligations ($M)($M) | 6.30 | 9.20 | 7.90 | 19.4 | 9 | 28.7 | 54.3 | 35.9 | 66.2 | 70.4 | 54.1 | 31.6 | |
Department of Health and Human Services (HHS) Obligations ($M)($M) | 0.20 | 0.20 | 0.10 | 0.30 | 0.30 | -15.9 | -0.10 | 0.40 | -0.10 | 1 | 0.10 | 0.60 | |
Department of Justice (DOJ) Obligations ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | ||||
McKesson Corporation (MCK) — Consolidated Revenue ($M)($M)3 | 110,957 | 105,380 | 96,295 | 106,158 | 103,150 | 97,827 | 90,823 | 95,294 | 93,651 | 79,283 | 76,355 | 80,898 | |
McKesson (MCK) — GAAP Operating Income/(Loss) ($M)($M) | 1,604 | 1,319 | 2,150 | 1,619 | 1,407 | 1,036 | 1,591 | 1,224 | 578 | 1,029 | 1,216 | 642 | |
McKesson (MCK) — GAAP Net Income/(Loss) ($M)($M) | 1,218 | 614 | 1,682 | 1,186 | 1,110 | 784 | 1,260 | 879 | 241 | 915 | 791 | 589 | |
McKesson (MCK) — Merchandise Inventories, Net ($M)($M) | 28,217 | 26,259 | 24,207 | 27,067 | 26,134 | 25,065 | 23,001 | 23,837 | 24,176 | 25,571 | 21,139 | 22,020 | |
Cencora, Inc. (COR) — Consolidated Revenue ($M)($M)3 | 84,755 | 78,356 | 85,932 | 83,729 | 80,664 | 75,454 | 81,487 | 79,050 | 74,241 | 68,414 | 72,253 | ||
Cencora (COR) — GAAP Operating Income ($M)($M) | 1,120 | 1,143 | 760 | 18.5 | 868 | 1,036 | 706 | 127 | 673 | 553 | 823 | ||
Cencora (COR) — GAAP Net Income ($M)($M) | 764 | 1,641 | 560 | -340 | 687 | 718 | 489 | 3.40 | 484 | 421 | 602 | ||
Cencora (COR) — Merchandise Inventories ($M)($M) | 21,030 | 20,010 | 24,079 | 20,493 | 20,138 | 18,966 | 20,508 | 18,999 | 18,302 | 17,631 | 18,652 | ||
Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M)($M)3 | 1,494 | 1,442 | 1,351 | 1,465 | 1,435 | 1,416 | 1,333 | 1,346 | 1,279 | 1,227 | 1,146 | 1,124 | |
Accendra Health, Inc. (formerly Owens & Minor, OMI) — Revenue ($M)($M)3 | 602 | 613 | 628 | 709 | 697 | 682 | 674 | 695 | 687 | 660 | 2,613 | -5,125 | |
Consolidated Revenue ($M)($M)13 | 67,513 | 63,672 | 60,940 | 65,627 | 64,009 | 60,159 | 54,878 | 55,264 | 52,277 | 59,867 | 54,868 | 57,442 | |
Consolidated Cost of Products Sold ($M)($M) | 64,917 | 61,112 | 58,442 | 63,230 | 61,690 | 57,957 | 52,755 | 53,323 | 50,375 | 57,985 | 52,933 | 55,588 | |
Consolidated Gross Profit ($M)($M) | 2,596 | 2,560 | 2,498 | 2,397 | 2,319 | 2,202 | 2,123 | 1,941 | 1,902 | 1,882 | 1,935 | 1,854 | |
Consolidated Distribution, Selling, General & Administrative Expenses ($M)($M) | 1,595 | 1,625 | 1,542 | 1,504 | 1,461 | 1,484 | 1,315 | 1,306 | 1,277 | 1,277 | 1,269 | 1,268 | |
GAAP Restructuring and Employee Severance ($M)($M) | 23 | 40 | 25 | 21 | 20 | 27 | 28 | 9 | 24 | 69 | 53 | 28 | |
GAAP Litigation (Recoveries)/Charges, Net ($M)($M) | 47 | 3 | -11 | 18 | 0 | 9 | 105 | 31 | 40 | -50 | -80 | 11 | |
Consolidated GAAP Operating Earnings/(Loss) ($M)($M) | 753 | 729 | 509 | 707 | 668 | 428 | 730 | 549 | 568 | 401 | 369 | 505 | |
Interest Expense, Net ($M)($M) | 73 | 79 | 101 | 88 | 80 | 74 | 74 | 35 | 32 | 9 | 28 | 3 | |
Earnings/(Loss) Before Income Taxes ($M)($M) | 688 | 554 | 392 | 630 | 598 | 384 | 665 | 511 | 541 | 391 | 342 | 512 | |
Provision for/(Benefit from) Income Taxes ($M)($M) | 132 | 154 | 12 | 159 | 144 | 141 | 157 | 110 | 124 | 158 | 80 | 143 | |
GAAP Net Earnings/(Loss) Attributable to Cardinal Health ($M)($M) | 554 | 398 | 399 | 467 | 450 | 239 | 506 | 400 | 416 | 235 | 261 | 368 | |
GAAP Diluted EPS Attributable to Cardinal Health ($)($) | 2.38 | 1.70 | 1.69 | 1.97 | 1.88 | 1 | 2.10 | 1.65 | 1.70 | 0.96 | 1.07 | 1.50 | |
Diluted Weighted-Average Common Shares (M)(M) | 233 | 236 | 237 | 239 | 241 | 243 | 245 | 245 | 246 | ||||
Cash Dividends Declared per Common Share ($)($) | 0.52 | 0.51 | 0.51 | 0.51 | 0.51 | 0.50 | 0.51 | 0.51 | 0.51 | 0.50 | 0.50 | 0.50 | |
Total Assets ($M)($M)7 | 59,544 | 57,299 | 56,689 | 58,083 | 55,228 | 53,122 | 49,871 | 47,002 | 43,059 | 45,121 | 45,880 | 46,573 | |
Net Cash Provided by Operating Activities ($M)($M)5 | 1,398 | 1,692 | 1,823 | 686 | 973 | 1,520 | 2,920 | -396 | -1,647 | 2,082 | -27 | 1,179 | |
5 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Cardinal Health, Inc. reports on a fiscal year ending June 30 (Q1: Jul–Sep, Q2: Oct–Dec, Q3: Jan–Mar, Q4: Apr–Jun); latest reported period is Q1 FY27 (ended September 30, 2026) and latest completed fiscal year is FY2026 (ended June 30, 2026).
- Effective Q3 FY2024, Cardinal Health reorganized its operating structure into three reportable categories: Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and Other (comprising three high-margin growth operating segments: at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics). Historical pre-reorganization Pharmaceutical and Medical segment series are preserved separately through Q2 FY24.
- Only directly published point figures and cumulative year-to-date period splits (`quarter = year-to-date − previous year-to-date` and `Q4 = full year (10-K) − nine months (10-Q)` on cash flow and cumulative footnote schedules) are included; no self-computed ratios, margins, or growth rates are added. Consolidated-minus-standalone parent subtraction is not applicable because Cardinal Health, Inc. files consolidated U.S. GAAP financial statements as a holding parent without standalone parent operating revenue.
- Peer SEC XBRL quarterly series for McKesson (MCK, March 31 FYE), Cencora (COR, September 30 FYE), Option Care Health (OPCH, December 31 FYE), and Accendra Health / Owens & Minor (OMI, December 31 FYE) are aligned by calendar quarter-end dates to Cardinal Health's fiscal quarters for apple-to-apple comparison.
Không hiện vì thiếu các kỳ gần đây (10)
- Core Growth Businesses › at-Home Solutions Patient Count — Disclosed only as an approximate lower bound ('over 3 million patients' / 'more than 3 million patients annually') in Form 10-K and Investor Day materials
- Core Growth Businesses › Solaris Health & Specialty Alliance MSO Provider & Site Counts — Disclosed as bounds ('more than 750 providers across more than 250 practice locations') or single-point transaction announcements ('~3,000 providers in 32 states') without a continuous multi-period series
- Core Growth Businesses › Nuclear & Precision Health Solutions Pipeline & Clinical Trials — Disclosed as bounds ('more than 70 pipeline products', 'more than 15 Actinium-225 clinical trials') or single-quarter rollout targets ('130 radiopharmacies targeted by end of FY27')
- Core Growth Businesses › ContinuCare Pathway Retail Pharmacy Network — Disclosed only as single-point bounds ('over 11,000 retail and grocery pharmacies', 'nearly 1,400 Publix pharmacies') in January 2026 conference update
- Core Growth Businesses › U.S. Distribution & Manufacturing Facility Counts — Form 10-K Item 2 qualitative text ('one national logistics center and a number of primary pharmaceutical and specialty distribution facilities') does not report exact annual facility counts
- Guidance Tracker › GMPD FY26 Segment Profit Guidance in Q4 FY25 & Q1 FY26 — Expressed only as a lower bound ('$140M+') prior to Q2 FY26 point/range disclosures
- Governance › Board & Committee Average Attendance Rate (%) — Disclosed in the 2025 Proxy Statement only as a lower bound ('Exceeded 96% overall average attendance')
- Environmental & Sustainability › Corporate Sustainability Report PDFs (cardinalhealth.com) — Corporate marketing CDN (www.cardinalhealth.com/content/dam) blocks automated connections via Akamai Bot Manager tarpit
- Segment Economics, ASU 2023-07 Cost Structure & Geographic Footprint › Total Reportable Segments Profit ($M) › Total Reportable Segments Revenue ($M) — Discontinued or insufficient consecutive latest periods
- Customer/Supplier Concentration, Opioid Liabilities, Working Capital, Leases & Governance › Share of Merchandise Inventories Valued Under LIFO Method (%) › Unrecognized LIFO Inventory Excess Over Average Cost ($M) — Discontinued or insufficient consecutive latest periods
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Core Growth Businesses, Distribution Drivers & Workforce Network
Segment Economics, ASU 2023-07 Cost Structure & Geographic Footprint
- Pharmaceutical and Specialty Solutions — Segment Revenue ($M) ($M)21 kỳ
- Global Medical Products and Distribution (GMPD) — Segment Revenue ($M) ($M)21 kỳ
- Other Segment (NPHS, at-Home & OptiFreight) — Total Segment Expenses ($M) ($M)9 kỳ
- Total Reportable Segments Profit ($M) ($M)21 kỳ
- United States Revenue ($M) ($M)17 kỳ
- Legacy Pharmaceutical Segment Revenue (Pre-Q3 FY24 Structure, $M) ($M)9 kỳ
- Legacy Medical Segment Revenue (Pre-Q3 FY24 Structure, $M) ($M)9 kỳ
Non-GAAP Performance, Pre-Tax Adjustment Bridge, Adjusted FCF & Guidance Tracker
Customer/Supplier Concentration, Opioid Liabilities, Working Capital, Leases & Governance
Subsidiary Statutory Filings — Cardinal Health U.K. 432 Limited
Federal Contract Awards, U.S. Healthcare Distribution Macro & Peer Benchmarks
- Federal Prime Contract Obligations to Cardinal Health ($M) ($M)99 kỳ
- U.S. Drug & Druggists' Sundries Merchant Wholesalers Sales — NAICS 4242 ($M) ($M)103 kỳ
- U.S. Retail Pharmacies and Drug Stores Monthly Sales — NAICS 44611 ($M) ($M)104 kỳ
- U.S. PPI: Pharmaceutical Preparations (Index) (×)105 kỳ
- McKesson Corporation (MCK) — Consolidated Revenue ($M) ($M)26 kỳ
- Cencora, Inc. (COR) — Consolidated Revenue ($M) ($M)25 kỳ
- Option Care Health, Inc. (OPCH) — Consolidated Revenue ($M) ($M)26 kỳ
- Accendra Health, Inc. (formerly Owens & Minor, OMI) — Revenue ($M) ($M)26 kỳ
Consolidated GAAP Financial Statements
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Cardinal Health
- CAH SEC Form 10-K (filed 2026-08-11) ↗
- CAH SEC Form 10-Q (filed 2026-11-05) ↗
- CAH SEC Form 8-K (filed 2026-11-05) ↗
- CAH SEC Form 8-K (filed 2026-08-11) ↗
- Cardinal Health U.K. 432 Limited — Companies House 01278801 Statutory Accounts (2025, filed 25 Mar 2026) ↗
- USAspending.gov — Federal Prime Contract Award Obligations to Cardinal Health ↗
- CAH SEC Form 8-K (filed 2024-02-01) ↗
- CAH SEC Form 8-K (filed 2023-08-15) ↗
- ir_pres_FY2027Q1_Q1-FY27-Earnings-Presentation-FINAL.pdf ↗
- FRED (S4242SM144NCEN) — U.S. Wholesale Sales: Drugs and Druggists' Sundries (NAICS 4242, $M) ↗
- FRED (MRTSSM44611USN) — U.S. Retail Sales: Pharmacies and Drug Stores (NAICS 44611, $M) ↗
- FRED (WPU0638) — U.S. PPI: Pharmaceutical Preparations (Index) ↗
See a number that looks wrong?